# MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

> **NCT05007106** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 613 (actual)

## Conditions studied

- Uterine Cervical Neoplasms
- Endometrial Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Gallbladder Neoplasms
- Cholangiocarcinoma
- Esophageal Neoplasms
- Triple Negative Breast Neoplasms
- Hepatocellular Carcinoma
- Urinary Bladder Neoplasms
- Ovarian Neoplasms
- Stomach Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab/Vibostolimab Co-Formulation
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** 5-Fluorouracil
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05007106
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-16
- **Primary completion:** 2025-08-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 613 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007106, "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05007106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*